SPC300

Siponimod

  • Status:
    Veitt
  • Application date:
    23.6.2020
  • Application published:
    15.7.2020
  • Grant published:
    15.3.2021
  • Max expiry date:
    20.12.2034
  • Medicine name:
    Mayzent
  • Medicine for children:
    No

Timeline

Today
23.6.2020Application
15.7.2020Publication
15.3.2021Registration
20.12.2034Expires

Marketing license

  • IS authorization number:
    EU/1/19/1414/001-002; EU/1/19/1414/003
  • Date:
    21.1.2020
  • Foreign authorization number:
    EU/1/19/1414
  • Date:
    13.1.2020

Owner

  • Name:
    Novartis AG
  • Address:
    Lichtstrasse 35, Basel CH

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113 Reykjavík

Patent

Upload documents